Self-efficacy in bipolar disorder: Development and validation of a self-report scale.

J Affect Disord

Peel & Rockingham Kwinana Mental Health Service, Rockingham, Australia.

Published: February 2020

Background: Successful management of bipolar disorder (BPD) typically involves individuals undertaking a complex array of self-management tasks (e.g., taking medication, monitoring symptoms, following a regular sleep routine). Many people with BPD doubt they can successfully undertake these tasks. This low sense of self-efficacy may lead to the perpetuation of BPD symptoms, poor quality of life, and low adherence to treatment. Research on self-efficacy in BPD has been hampered by the lack of a short, reliable and valid self-report scale that is practical to use in clinical and research settings. We sought to develop such a scale.

Methods: BPD patients (N = 303) completed a new battery of items measuring their self-efficacy for performing BPD self-management tasks. Modern psychometric techniques such as bifactor analyses were used to refine the scale, determine an appropriate scoring algorithm, and establish reliability and validity.

Results: The Bipolar Self-Efficacy Scale (BPSES) comprises 17 items. BPSES scores were reliable, sensitive to change, and correlated with theoretically related constructs such as social adjustment and positive affect. BPSES scores had substantially higher associations with depression and quality of life than an alternative instrument that measured self-efficacy in general, rather than self-efficacy specifically related to bipolar disorder self-management.

Limitations: Patients were required to be medically managed while attending adjunctive psychological treatment of BPD.

Conclusions: The BPSES is a brief scale that can be used to reliably and validly measure bipolar self-efficacy. It may be fruitful to use the scale in clinical practice, and studies investigating treatment outcomes, mechanisms, and moderators.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jad.2019.10.026DOI Listing

Publication Analysis

Top Keywords

bipolar disorder
12
self-efficacy
8
self-efficacy bipolar
8
self-report scale
8
self-management tasks
8
quality life
8
bipolar self-efficacy
8
bpses scores
8
scale
6
bpd
6

Similar Publications

The Neurodiversity Framework in Medicine: On the Spectrum.

Dev Neurobiol

January 2025

Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.

The term "neurodiversity" refers to the natural heterogeneity in human neurological functioning, which includes neurodevelopmental differences and other mental health conditions (e.g., autism spectrum disorder [ASD], attention-deficit hyperactivity disorder [ADHD], dyslexia, bipolar disorder, schizophrenia, and depression).

View Article and Find Full Text PDF

Abnormal network homogeneity in patients with bipolar disorder in attention network.

Brain Imaging Behav

January 2025

Key Laboratory of Adolescent Cyberpsychology and Behavior (Ministry of Education), Wuhan, China.

Bipolar disorder (BD) is a complex psychiatric condition marked by significant mood fluctuations that deeply affect quality of life. Understanding the neural mechanisms underlying BD is critical for improving diagnostic accuracy and developing more effective treatments. This study utilized resting-state functional magnetic resonance imaging (rs-fMRI) to investigate functional connectivity within the ventral and dorsal attention networks in 52 patients with BD and 51 healthy controls.

View Article and Find Full Text PDF

Introduction Psychoeducation is a form of psychosocial treatment with proven efficacy in preventing the relapse of bipolar disorder (BD). However, the effectiveness of psychoeducation has not been verified in Japan. We aimed to examine the effect of a brief group psychoeducation course (eight-session long) on relapse prevention in Japanese patients with BD and associated factors.

View Article and Find Full Text PDF

Background: Atypical antipsychotics are a common treatment for serious mental illness, but many are associated with adverse effects, including weight gain and cardiovascular issues, and real-world experience may differ from clinical trial data. Cariprazine has previously demonstrated a favorable safety and tolerability profile in clinical trials. Here, we evaluated the effects of cariprazine on body weight and blood pressure for bipolar I disorder (BP-I), schizophrenia, or as adjunctive treatment for major depressive disorder (MDD) using real-world data.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!